Migraine Treatment With Reyvow
This treatment for migraines with Reyvow is a significant discovery. It is the first treatment for migraines that has been approved by the FDA in more than two decades.
Reyvow is a medicine that contains the active ingredient lasmiditan. Its mechanism of action is different from that of other drugs used in the treatment of acute migraine.
It is a new class of treatment for acute migraine. The novelty is that it is the only drug in his family with FDA approval. Because it is a 5-HT1F receptor agonist, it acts both centrally and peripherally.
Several studies have been conducted, and the results showed that a higher percentage of patients treated with Reyvow escaped migraines two hours after the first dose, compared with study participants taking a placebo.
What is a migraine?
A migraine is a type of severe headache that affects women the most. It is a pain located most often in the middle of the head. It usually involves other symptoms.
Symptoms of migraines include nausea, vomiting and sensitivity to light. Some migraines occur without aura; those with aura often prevent individuals from continuing their activities and significantly diminish their quality of life.
It is normal for patients with migraines to undergo several phases of treatment. Experts recommend combining drug treatment with alternative therapies or techniques to avoid side effects.
Migraine treatment with Reyvow
The drug comes in the form of tablets with two different concentrations, 50 mg and 100 mg. The most common side effects are dizziness, fatigue, drowsiness, nausea, vomiting and muscle weakness.
In addition, because the drug acts on the central nervous system, while you are under treatment, you do not have to drive or perform tasks that require a lot of attention. For this reason, you must be careful if you have to use machines at least 8 hours after taking Reyvow.
How does this migraine treatment work with Reyvow?
Lasmiditan binds to the 5-HT1F receptor and acts both centrally and peripherally. It works by reducing the release of substances called neuropeptides. In addition, it influences the pathways of pain without vasoconstriction in the brain.
The drug was approved based on the results of phase III studies, which involved a total of 3,177 patients with migraines, both with and without aura.
The FDA noted that the data obtained showed that patients whose symptoms were pain, nausea and sensitivity to light felt better after taking lasmiditan.
In just two hours and with a single dose, this drug was able to quickly and completely eliminate the pain. It is also effective in controlling and relieving migraine-associated symptoms, such as auras.
Reyvow and migraines
Migraine can prevent you from performing your daily tasks. People who suffer from migraines face attacks that can be very intense and painful, forcing them to stop their daily activities. With a single dose, Reyvow offers the possibility to quickly and completely eliminate the pain from moderate to severe migraine in just 2 hours.
Reyvow is a non-opioid and non-narcotic drug and, according to data currently available, its use does not create physical dependence.
Adverse effects
Difficulty treating migraine
Reyvow is a medicine that reduces moderate to severe headaches within two hours of administration. It also has the advantage of not producing photophobia or nausea. It is currently a breakthrough in the treatment of migraines, being an excellent option for these patients.
